The University of Chicago Header Logo

Connection

Olatoyosi Odenike to Clinical Trials, Phase I as Topic

Back to Details
This is a "connection" page, showing publications Olatoyosi Odenike has written about Clinical Trials, Phase I as Topic.
Olatoyosi Odenike
Connection Strength
0.053
Clinical Trials, Phase I as Topic
  1. Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy. Adv Sci (Weinh). 2023 08; 10(23):e2300445.
    View in: PubMed
    Score: 0.053
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.